Indication
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
In other countries
The same active substances on other registers, the same brand first.
National listings
The national registers that list this EU medicine.
- Forsteo 20 Microgramos/80 Microlitros, Solucion InyectableSpain · 250 µg · solución inyectable en pluma precargada · Eli Lilly Nederland B.V. · MarketedSame brand
- Forsteo 20 Microgramos/80 Microlitros, Solucion InyectableSpain · 250 µg · solución inyectable en pluma precargada · Eli Lilly Nederland B.V. · AuthorisedSame brand
- ForsteoCroatiaSame brand